Recent Progress in Research on the Pharmacological Potential of Mushrooms and Prospects for Their Clinical Application

The Cardioprotective Properties of Agaricomycetes Mushrooms Growing in the Territory of Armenia: Review

“…anti-oxidative, antiinflammatory, anti-atherosclerotic, anti-hypertensive, anti-obesity, hypoglycemic, hypolipidemic and fibrinolytic) may be clinically relevant in the prevention and treatment of cardiac diseases. 3,4,11,14,15,[37][38][39][40][41][42][43] The maintenance of balance between free radical production and antioxidant defence is an essential condition for normal functioning of biological organisms. Free radicals may damage cellular lipids, proteins, and DNA, affect their normal function and lead to the development of various diseases.…”

“…They neutralize free radical elements by enhancing the activity of catalase and superoxide dismutase, and stabilize glutathione and malondialdehyde levels. 12 3,4,[11][12][13][14][15][16]27,30,35,39,40 The lanostane type triterpenoids isolated from Ganoderma lucidum were suggested as promising bioactive agents for the treatment of MS. 6 In vitro study and animal assays, as well as several human trials suggest that Agaricus bisporus G. lucidum, H. erinaceus, Phellinus linteus and Pleurotus species may normalize blood glucose and lipid levels. 4,[16][17][18]20,21 The eritadenine extracted from L. edodes has been identified…”

“…55 The research data provide evidence for the usage of mushrooms as a healthy food to decrease the risk of MS and CVD. 4,29,[31][32][33] Mushroom-rich diet regulates some risk factors associated with cardiac diseases, such as the levels of total low-density lipoprotein (LDL), high-density lipoprotein (HDL), total cholesterol, fasting triacylglycerol, homocysteine, AH, as well as the oxidative and inflammatory damage of vessels. [37][38][39] With this treatment approach of CVD, several agaricoid and polyporoid MM, such as Chaga (Inonotus obliquus), Lion's Mane (H. erinaceus), Oyster mushroom (P. ostreatus), Maitake (G. frondosa), Turkey tail [Coriolus (=Trametes) versicolor], Reishi (G.…”

“…lucidum), Shiitake (L. edodes), and Agarikon (Laricifomes officinalis) are considered potential natural products to develop myco-pharmaceuticals with CPE. 4,8,19,23,39,53,[56][57][58][59] Among these species, G. frondosa, G. lucidum, L. edodes, P. ostreatus, and P. pulmonarius are considered ideal products with low-calorie healthy diet to prevent the development of CVD due to high contents of fibres, proteins, and microelements. [31][32][33] In particular, Pleurotus species decrease the levels of LDL and HDL, homocysteine, total cholesterol, and fasting triglycerides, prevent the development of AH, diabetes, and other pathological conditions, as well as reduce oxidative stress.…”

“…[31][32][33] In particular, Pleurotus species decrease the levels of LDL and HDL, homocysteine, total cholesterol, and fasting triglycerides, prevent the development of AH, diabetes, and other pathological conditions, as well as reduce oxidative stress. 3,4,39 A pronounced HCE of P.…”